Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study

<p>Abstract</p> <p>Background</p> <p>Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) significantly reduces the relapse rate and disability progression, and improves health-related quality of life (HRQoL), in patients with relapsing-remitting multiple scleros...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Stephenson Judith J, Kern David M, Agarwal Sonalee S, Zeidman Ruth, Rajagopalan Krithika, Kamat Siddhesh A, Foley John
Format: Artigo
Idioma:Inglês
Publicat: BMC 2012-12-01
Col·lecció:Health and Quality of Life Outcomes
Matèries:
Cognitive function
Health-related quality of life
Multiple sclerosis
Natalizumab
Patient-reported outcomes
Accés en línia:http://www.hqlo.com/content/10/1/155
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars